Helping clients meet their business challenges begins with an in-depth understanding of the industries in which they work. That’s why KPMG LLP established its industry-driven structure. In fact, KPMG LLP was the first of the Big Four firms to organize itself along the same industry lines as clients.

How We Work

We bring together passionate problem-solvers, innovative technologies, and full-service capabilities to create opportunity with every insight.

Learn more

Careers & Culture

What is culture? Culture is how we do things around here. It is the combination of a predominant mindset, actions (both big and small) that we all commit to every day, and the underlying processes, programs and systems supporting how work gets done.

Learn more

Maximizing the potential of your generic portfolio strategy

The Inflation Reduction Act may usher in a new era of growth for generics manufacturers

Subscribe to receive Elevate C-Suite Perspectives alerts

The recently passed Inflation Reduction Act (IRA) may create a more attractive market for generics companies to consider innovative portfolio strategy management. During the four years before the IRA is in full effect, drugmakers may want to consider developing innovative generic drugs, as well as generic alternatives to reference products on the list of IRA-impacted drugs. Approached strategically, such efforts can help companies balance their portfolios, open new revenue streams, and better prepare for revenue cycle implications.

In this paper, we offer three considerations generic drug manufacturers should keep in mind as they evolve their portfolios to include the next generation of accessible and affordable prescription drugs:

  • Value creation through portfolio management and differentiation
  • Manufacturing investments for a sustainable supply chain
  • Strategic scaling to drive share and margin

As you consider these insights from our life sciences team, it should become clear that, while patent expirations for blockbuster drugs are on the decline, the need for low-cost prescription drugs is more acute than ever.

Image of Jeff Stoll

Jeff Stoll

Principal, National Strategy Life Sciences Leader

Image of

Media contacts

Discover related insights and services

Thank you!

Thank you for contacting KPMG. We will respond to you as soon as possible.

Contact KPMG

Use this form to submit general inquiries to KPMG. We will respond to you as soon as possible.

By submitting, you agree that KPMG LLP may process any personal information you provide pursuant to KPMG LLP's Privacy Statement.

An error occurred. Please contact customer support.

Job seekers

Visit our careers section or search our jobs database.

Submit RFP

Use the RFP submission form to detail the services KPMG can help assist you with.

Office locations

International hotline

You can confidentially report concerns to the KPMG International hotline

Press contacts

Do you need to speak with our Press Office? Here's how to get in touch.